Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma
复制标题
DOI：
10.3109/10428194.2011.627481
复制
发表时间：
2012-04-01
影响因子：
2.6
通讯作者：
Griskevicius, Laimonas
中科院分区：
文献类型：
--
作者：
Peceliunas, Valdas;Janiulioniene, Ausra;Griskevicius, Laimonas
外周血恶性循环浆细胞（cpc）的预处理检测已被证明对多发性骨髓瘤（MM）具有阴性预后价值。我们假设使用六色流式细胞术评估一个治疗周期的CPC动力学可能有助于早期发现MM对治疗的难治性。42例难治性或复发性（RR） MM患者入组。与aCPCs减少（中位TTP 258天，OS 856天）或无法检测到（中位TTP 581天，OS 1006天）的患者（TTP和OS分别p < 0.001和p = 0.007）相比，一个治疗周期后，异常表型（aCPCs） cpc未减少的患者的中位肿瘤进展时间（TTP）为51天，中位总生存期（OS）为308天。在第一个治疗周期后，RR型MM患者的aCPCs未降低可能有助于早期识别对特定治疗有耐药性的患者。
Pretreatment detection of peripheral blood malignant circulating plasma cells (CPCs) has been shown to be of negative prognostic value in multiple myeloma (MM). We hypothesized that the assessment of CPC kinetics in response to one therapy cycle using six-color flow cytometry could be helpful in the early detection of MM refractoriness to treatment. Forty-two patients with refractory or relapsed (RR) MM were enrolled. Median time to tumor progression (TTP) of 51 days and median overall survival (OS) of 308 days was shortest in patients whose CPCs with aberrant phentoype (aCPCs) did not decrease after one therapy cycle compared to patients with decreasing (median TTP 258 days and OS 856 days) or undetectable (median TTP 581 days and OS 1006 days) aCPCs (p < 0.001 and p = 0.007 for TTP and OS, respectively). Non-reduction of aCPCs in patients with RR MM after the first cycle of therapy may be useful in early identification of patients resistant to a given therapy.